Deep Genomics Scores $180M To Deliver AI Programmed RNA Therapies

With COVID-19 vaccines making RNA-based medicines a household name, Deep Genomics is reaping some of the buzz—as well as $180 million in new funding for its efforts to develop “programmable” therapies. The artificial intelligence firm’s series C round more than quadruples its previous $40 million fundraising from early January 2020, and will help advance at…